Amgen submits talimogene MAA

Amgen Inc. (NASDAQ:AMGN) submitted an MAA to EMA for talimogene laherparepvec to treat regionally and distantly metastatic melanoma. In July, Amgen disclosed that it submitted a BLA to FDA for the modified herpes simplex virus type 1 (HSV-1) encoding GM-CSF. ...